RERE-AS1 as a regulator of immune modulation and therapeutic response in breast cancer.

A p -value < 0.05 was considered statistically significant, and p < 0.01 was considered highly significant.

also in 132,142 other papers

Results LncRNA RERE-AS1 is downregulated across multiple cancer types, particularly in BRCA Analysis of transcriptome data from 33 tumor types and corresponding normal tissues in the TCGA database demonstrated that RERE-AS1 expression was significantly downregulated in multiple cancers, including BRCA, COAD, KICH, KIRC, LIHC, LUSC, PCPG, PRAD, and THCA, with a decreasing trend also observed in LAML (Figure S2 A, B).

also in 47,180 other papers